Congratulations to Jeremy Simonetto (Year 8, St Patricks College) for being runner up in the 2020 UNSW Bragg Student Prize for Science Writing.
Year 8 student at St Patricks College, Jeremy Simonetto, discusses the potential planet-changing uses for iPS cells in medical research in his entry, awarded runner-up in the UNSW Bragg Student Prize for Science Writing, under the 2020 theme The Big Ideas Saving the Planet.
Well-structured, with a coherent narrative, Jeremy offers a useful fly-through of the potential and pitfalls of stem cell research, stresses one of the 2020 judges, science writer and editor Sara Phillips.
Read Jeremys full essay below.
RELATED: How one school is using the Bragg science writing prize to challenge gifted students
Imagine a future where genetic diseases are a thing of the past. Where conditions like leukemia can be cured in one treatment, and tissue grafts can be made bespoke to-order. A future that could be possible with the advent of induced pluripotent stem cells (or iPS cells for short), which have the potential to revolutionise in the field of medicine.
Induced pluripotent stem cells are skin or blood cells that have been genetically reprogrammed to become stem cells in other words, cells that can become any other bodily cell. Through inserting genes into the initial skin or blood cells, they begin a 23 week-long process in which the cell slowly converts back into a pluripotent state a stem cell. From there, these cells are converted into embryoids, structures similar to early embryos. Then, after a few weeks, they are diverted to become particular cells, such as muscle or brain cells.
The introduction of iPS cells can provide a solution to an important ethical problem. Scientists are now starting to use iPS cells to make organoids or miniature versions of organs. These organoids can then be used as model environments for the testing of new medicines. But, what does this have to do with ethics? Well, theres hope that these organoids can provide an alternative to animal testing, a cruel method of trialling drugs to ensure they are safe for use in humans. Additionally, testing on organoids is more accurate than on animals, as animals sometimes respond differently to humans, an instrumental factor in determining if a drug is okay for use by people.
These iPS cell-derived organoids also have another use, which is currently under development. They can be used to model diseases in lab conditions, tracking the exact causes, spread and behaviour of sicknesses ranging from the common cold to malignant cancer. It works through creating a miniature copy of an organ before exposing it to a disease. From there, scientists watch the progression of the disease from its earliest stages up until its critical mass, studying how the body reacts. And this information can have amazing results. It can help researchers gain a better insight into the immune system and see how it responds to threats. It also helps to see what causes cancers to form and spread, to find ways to prevent and stop this from happening. Even now, scientists are modelling COVID-19 on organoids, to see why certain people have different reactions to the virus, why and how it infects and spreads around the body, and understand why it causes long-lasting damage to patients even after theyve recovered.
Thats not all, however. iPS cells also help scientists to understand genetic diseases and how they are caused. By studying organoids, scientists can see when the earliest traces of genetic conditions emerge in a persons cells. For many of these diseases, which start to appear during foetal development, such as haemophilia, cystic fibrosis, Tay-Sachs disease, and muscular dystrophy, it could provide an insight into how they come about. With further research, it could even lead to ways of preventing these diseases in the womb before they even develop. A true medical ethos prevention better than cure.
Even with something as significant as this, weve only scratched the surface. There is hope that iPS cells themselves could provide the pathway to treating many serious illnesses. This can be done through transplants that do not rely on the patients acceptance or rejection of new cells because they are derived from their own. An example of this is in bone marrow diseases, such as leukemia. By making healthy bone marrow cells from already-existing skin cells, they can then be transplanted to replace the cancerous cells without the need for anti-rejection drugs. This is critical because many of these drugs involve strong immune suppression, which drastically weakens a persons immune response, and has to be taken for the rest of their life. Additionally, in patients who cant take anti-rejection drugs (for example, as a result of medical complications or health conditions) it will increase the transplants rate of success because it does not rely on the risky chance of acceptance. The same principle with bone marrow diseases can be applied to treat a myriad of other conditions, from cirrhosis to Type 1 diabetes.
RELATED: Bragg judges reveal their top 3 writing tips
But, while all these potential advancements are within our grasp, how could this change the future for our planet? Well, when you look at it, the possibilities of iPS cells are endless. The diseases mentioned above are just a few of the thousands that iPS cells could help to treat. It could revolutionise medicine, taking conditions we now think of as fatal and providing cures, potentially saving millions of lives. Even making certain diseases extinct forever. iPS cells, the stem of the future.
For the2020 UNSW Bragg Student Prize for Science Writing we asked Australian high school students to enter 800-word essays responding to the 2020 theme of saving the planet, identifying and discussing a problem in the world that has yet to be solved by contemporary science and technology.
This article was written by a STEM Contributor for Careers with STEM. To learn more, please visit our contact page.
Read more here:
iPS Cells: The STEM of the Future - Careers with STEM
- Engineered heart muscle allografts for heart repair in primates and humans - Nature.com - January 31st, 2025
- Rapid and scalable personalized ASO screening in patient-derived organoids - Nature.com - January 23rd, 2025
- Multifactorial approach is needed to unravel the maturation phases of human neurons derived from induced pluripotent stem cells - Nature.com - January 21st, 2025
- Unlock the Potential of iPSC Differentiation with Creative Biolabs - EIN News - January 17th, 2025
- Automated iPS Cell Production to Start in Japan in April - Nippon.com - January 9th, 2025
- iPSCs: take the survey and win! - RegMedNet - January 9th, 2025
- Automated iPS cell production to start in Japan in April - The Japan Times - January 9th, 2025
- Dysregulation of mTOR signalling is a converging mechanism in lissencephaly - Nature.com - January 1st, 2025
- BrightPath-Cellistic partner for clinical trial advancements of CAR-T cell therapy - Yahoo Finance - December 17th, 2024
- Restoring Vision: The Promise of Stem Cells in Healing Blindness - This is Local London - December 15th, 2024
- BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT... - December 13th, 2024
- Induced Pluripotent Stem Cells: Problems and Advantages when Applying ... - December 7th, 2024
- What are Induced Pluripotent Stem Cells? | ISCRM - December 7th, 2024
- Induced pluripotent stem cells, a giant leap for mankind therapeutic ... - December 7th, 2024
- Advantages and disadvantages of induced pluripotent stem cells - December 7th, 2024
- Generation and long-term culture of human cerebellar organoids from pluripotent stem cells - Nature.com - December 3rd, 2024
- Whats the secret to living to 100? Centenarian stem cells could offer clues - Nature.com - December 1st, 2024
- Single-cell RNA sequencing reveals key regulators and differentiation trajectory of iPSC-derived cardiomyocytes - Nature.com - November 26th, 2024
- Cell therapy weekly: GMP certification of iPSC-focused manufacturing facility - RegMedNet - November 25th, 2024
- Takeda and Alloy Therapeutics partner to make off-the-shelf CAR-T therapies - Pharmaceutical Technology - November 22nd, 2024
- Alloy Therapeutics, Takeda Partner on Revolutionary iPSC Cell Therapy Platform | TAK Stock News - StockTitan - November 22nd, 2024
- A remarkable study was released this week. It is a Japanese researcher's paper that restored vision - - November 18th, 2024
- World's first stem cell treatment restores vision, offers new hope to the blind - India Today - November 12th, 2024
- The Breakthroughs of Vision Restoration - The New Importance of Stem Cells - Yahoo News UK - November 12th, 2024
- Modified stem cell therapy aids motor function in mice with... - Parkinson's News Today - October 30th, 2024
- Team achieves successful reproduction of hematopoietic stem cell developmental process in an in vitro culture system - Phys.org - October 22nd, 2024
- Human Pluripotent Stem Cells (iPSC) Generation, Culture, and ... - October 11th, 2024
- Induced pluripotent stem cell technology: a decade of progress - October 11th, 2024
- Nobel Winner Shinya Yamanaka: Cell Therapy Is Very Promising For Cancer, Parkinsons, More - Forbes - October 10th, 2024
- Human Induced Pluripotent Stem Cells : Clinical Significance and ... - October 6th, 2024
- Induced pluripotent stem cells: Mechanisms, achievements and ... - October 6th, 2024
- Induced pluripotent stem cells | UCLA BSCRC - October 6th, 2024
- Unlocking new regenerative pathways in iPS cellderived epicardium for cardiac repair - Medical Xpress - October 4th, 2024
- Artificial heart made of iPS cells unveiled to press, to be displayed at 2025 Osaka expo - The Mainichi - The Mainichi - October 2nd, 2024
- Trial planned on sparing diabetes patients from insulin injections - - September 30th, 2024
- Leveraging the power of iPS cell technology to study myeloid neoplasm - Medical Xpress - September 10th, 2024
- Kyoto University Hospital seeks to treat Type 1 diabetes using iPS cells - The Japan Times - September 4th, 2024
- Kyoto Hospital to Test Using Ips Cells to Treat Diabetes; Seeks to Reduce Burden of Multiple Daily Insulin Injections - The Japan News - September 4th, 2024
- Adaptive Biotechnologies to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants - August 24th, 2024
- Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine - August 24th, 2024
- Seer to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - August 24th, 2024
- Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference - August 24th, 2024
- Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024 - August 24th, 2024
- Kane Biotech to Release Second Quarter 2024 Financial Results on August 29, 2024 – Conference Call to Follow - August 24th, 2024
- Repligen Corporation to Present at Wells Fargo Healthcare Conference - August 24th, 2024
- Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing - August 24th, 2024
- Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies... - August 24th, 2024
- Novel insights from Human Induced Pluripotent Stem Cells on Origins and Roles of Fibro/Adipogenic Progenitors as Heterotopic Ossification Precursors -... - August 22nd, 2024
- Optimization of a human induced pluripotent stem cell-derived sensory neuron model for the in vitro evaluation of taxane-induced neurotoxicity -... - August 18th, 2024
- Culture Techniques for Drug Discovery and Therapeutics - Technology Networks - August 16th, 2024
- iPSC culture techniques for drug discovery and therapeutics - Labmate Online - August 12th, 2024
- Neuroprotective and anti-inflammatory properties of proteins secreted by glial progenitor cells derived from human iPSCs - Frontiers - August 6th, 2024
- G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 2nd, 2024
- Seventh patient cured of HIV: why scientists are excited - Nature.com - July 31st, 2024
- Purification technologies for induced pluripotent stem cell therapies - Nature.com - July 28th, 2024
- SIGA to Host Business Update Call on August 1 Following Release of Second-Quarter 2024 Financial Results - July 26th, 2024
- Twenty Lung Cancer Advocacy Organizations and 23andMe Come Together to Launch Lung Cancer Genetics Study to Help Advance Research - July 26th, 2024
- Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma - July 26th, 2024
- Collegium to Report Second Quarter 2024 Financial Results on August 8, 2024 - July 26th, 2024
- INmune Bio Inc. to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, August 1, 2024 - July 26th, 2024
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study - July 26th, 2024
- Windtree Therapeutics Provides Update on Istaroxime Clinical Development and Upcoming Clinical Trial Data - July 26th, 2024
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 - July 26th, 2024
- Inotiv, Inc. to Report Fiscal 2024 Third Quarter Financial Results and Host Conference Call on Thursday, August 8, 2024 - July 26th, 2024
- Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia - July 26th, 2024
- scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic... - July 26th, 2024
- Achieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 13, 2024 - July 26th, 2024
- Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience - July 26th, 2024
- Ipsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024) - July 26th, 2024
- Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment... - July 26th, 2024
- Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health... - July 26th, 2024
- Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027 - July 26th, 2024
- 60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support - July 26th, 2024
- California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2) - July 26th, 2024
- ISSCR 2024: iPS cell line panels can be isogenic and diverse - BioWorld Online - July 16th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - PR Newswire - July 10th, 2024
- KOS, I Peace, and Reju Enter Strategic Partnership to Develop Personalized Beauty Products Based on iPS Cells - The Manila Times - July 10th, 2024
- AIM ImmunoTech Announces Release of the Next CEO Corner Segment - July 5th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 5th, 2024
Recent Comments